CICC Medical: Maintains Bullish View on China Biotech Out-Licensing, Highlights Upcoming Q3 Earnings and ESMO

Bullish · $2359.HK · $1801.HK · $6160.HK · $6990.HK · $2696.HK

What Happened

CICC Medical released a note reiterating its positive stance on China's innovative pharma out-licensing (BD) theme, noting recent multi-billion-dollar deals by Chinese biotechs with multinationals. The broker also flagged the upcoming Q3 earnings season and the ESMO conference as potential catalysts.

Bottom Line

CICC Medical remains bullish on China's innovative pharma and out-licensing theme, recommending focus on CXO, innovative drugs, AI life sciences, and medical devices ahead of Q3 earnings and ESMO.

Free preview — more China A-share & HK research · About Us · Legal & Privacy